Pharmaceutical

Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 

Harmony is advancing pitolisant into a Phase III clinical trial that is expected to start in Q1 2024.

Feb 22, 2024 - 18:00
Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 
Harmony is advancing pitolisant into a Phase III clinical trial that is expected to start in Q1 2024.
Read the original article

Tags:

Previous Article

Immunocore and BMS partner to investigate first-line treatment for melanoma

Next Article

Immune-Onc’s antibody therapy collects second FDA orphan designation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Moderna-Merck mRNA cancer vaccine shows promise in combination with melanoma drug

STAT+: Moderna-Merck mRNA cancer vaccine shows promise ...

Apr 17, 2023

Imugene licenses potential first-to-market allogeneic CAR T for blood cancers

Imugene licenses potential first-to-market allogeneic C...

Aug 18, 2023

STAT+: Obesity specialists are scarce. Here’s how that’s starting to change

STAT+: Obesity specialists are scarce. Here’s how that’...

Aug 23, 2023